|
1
|
Mahjoub S, Baccouche H, Sahnoun M, Kaabi
H, Manai Z, Slama H and Ben Romdhane N: The JAK2 mutation in
myeloproliferative neoplasms: A predictive factor of thrombosis.
Tunis Med. 93:474–477. 2015.PubMed/NCBI
|
|
2
|
Sørensen AL and Hasselbalch HC: Antecedent
cardiovascular disease and autoimmunity in Philadelphia-negative
chronicmyeloproliferative neoplasms. Leuk Res pii: S0145-2126.
30555(5)2015.(Epub ahead of print).
|
|
3
|
Hofmann I: Myeloproliferative neoplasms in
children. J Hematop. 8:143–157. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Abelsson J, Andréasson B, Samuelsson J,
Hultcrantz M, Ejerblad E, Johansson B, Emanuel R, Mesa R and
Johansson P: Patients with polycythemia vera have worst impairment
of quality of life among patients with newly diagnosed
myeloproliferative neoplasms. Leuk Lymphoma. 54:2226–2230. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Shirane S, Araki M, Morishita S, Edahiro
Y, Ohsaka A and Komatsu N: Current problems in the diagnosis of
Philadelphia-negative myeloproliferative neoplasms in Japan. Rinsho
Ketsueki. 56:877–882. 2015.(In Japanese). PubMed/NCBI
|
|
6
|
Frederiksen H, Farkas DK, Christiansen CF,
Larsen TS, Hasselbalch HC, Stentoft J and Sørensen HT: Survival of
patients with chronic myeloproliferative neoplasms and new primary
cancers: A population-based cohort study. Lancet Haematol.
2:e289–296. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Yoshida M, Horiuchi M, Ueda H, Hagihara K,
Kanashima H, Nakao T, Hirata C, Inoue T and Yamane T: Cutaneous
extramedullary hematopoiesis associated with
myelodysplastic/myeloproliferativeneoplasm, unclassifiable. Rinsho
Ketsueki. 56:911–914. 2015.(In Japanese). PubMed/NCBI
|
|
8
|
Kiladjian JJ: Current therapies and their
indications for the Philadelphia-negative
myeloproliferativeneoplasms. Am Soc Clin Oncol Educ Book.
2015:e389–396. 2015. View Article : Google Scholar
|
|
9
|
Schmitt-Graeff AH: Chronic myeloid
neoplasms. Diagnostic criteria and current therapeutic concepts.
Pathologe. 31:29–41. 2010.(In German). View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Tefferi A and Vardiman JW: Classification
and diagnosis of myeloproliferative neoplasms: The 2008 World
Health Organization criteria and point-of-care diagnostic
algorithms. Leukemia. 22:14–22. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Baxter EJ, Scott LM, Campbell PJ, East C,
Fourouclas N, Swanton S, Vassiliou GS, Bench AJ, Boyd EM, Curtin N,
et al: Acquired mutation of the tyrosine kinase JAK2 in human
myeloproliferative disorders. Lancet. 365:1054–1061. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Jones AV, Kreil S, Zoi K, Waghorn K,
Curtis C, Zhang L, Score J, Seear R, Chase AJ, Grand FH, et al:
Widespread occurrence of the JAK2 V617F mutation in chronic
myeloproliferative disorders. Blood. 106:2162–2168. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Levine RL, Wadleigh M, Cools J, Ebert BL,
Wernig G, Huntly BJ, Boggon TJ, Wlodarska I, Clark JJ, Moore S, et
al: Activating mutation in the tyrosine kinase JAK2 in polycythemia
vera, essential thrombocythemia and myeloid metaplasia with
myelofibrosis. Cancer Cell. 7:387–397. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kralovics R, Passamonti F, Buser AS, Teo
SS, Tiedt R, Passweg JR, Tichelli A, Cazzola M and Skoda RC: A
gain-of-function mutation of JAK2 in myeloproliferative disorders.
N Engl J Med. 352:1779–1790. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
James C, Ugo V, Le Couédic JP, Staerk J,
Delhommeau F, Lacout C, Garçon L, Raslova H, Berger R,
Bennaceur-Griscelli A, et al: A unique clonal JAK2 mutation leading
to constitutive signalling causes polycythaemia vera. Nature.
434:1144–1148. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Levine RL and Wernig G: Role of JAK-STAT
signaling in the pathogenesis of myeloproliferative disorders.
Hematology Am Soc Hematol Educ Program. 233–239. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Bumm TG, Elsea C, Corbin AS, Loriaux M,
Sherbenou D, Wood L, Deininger J, Silver RT, Druker BJ and
Deininger MW: Characterization of murine JAK2V617F-positive
myeloproliferative disease. Cancer Res. 66:11156–11165. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Vardiman J, Brunning RD, Arber DA, et al:
Introduction and overview of the classification of the myeloid
neoplasms. WHO Classification of Tumours of Haematopoietic and
Lymphoid Tissues. Swerdlow SH, Campo E, Harris NL, et al: (Lyon,
France). IARC Press. 18–30. 2008.
|
|
19
|
Labastida-Mercado N, Galindo-Becerra S,
Garcés-Eisele J, Colunga-Pedraza P, Guzman-Olvera V, Reyes-Nuñez V,
Ruiz-Delgado GJ and Ruiz-Argüelles GJ: The mutation profile of
JAK2, MPL and CALR in Mexican patients with Philadelphia
chromosome-negative myeloproliferative neoplasms. Hematol Oncol
Stem Cell Ther. 8:16–21. 2015. View Article : Google Scholar : PubMed/NCBI
|
